With the growing understanding of numerous biologoical processes that are influenced by the 100 trillion microorganisms that make up the microbiome of an individual, there is an increasing number of Biotech and Pharma companies seeking to capitalize on this research to develop therapeutic, microbiome-based agents to treat disease. PharmaVentures' 'Bugs as Drugs' paper highlights important emerging deal as well as identifying some of the key players currently in the space.
 

Should you be interested in learning more about this subject or PharmaVentures please do not heditate to contact Kate Moore, the lead author.

Download This White Paper